Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Erratum to: Invest New Drugs

DOI 10.1007/s10637-017-0438-z

The article First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors, written by S. Fu, H. Hirte, S. Welch, T. T. Ilenchuk, T. Lutes, C. Rice, N. Fields, A. Nemet, D. Dugourd, S. Piha-Paul, V. Subbiah, L. Liu, J. Gong, D. Hong, and J. M. Stewart, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 01 February 2017 without open access.

With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 05 April 2017 to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Author information

Correspondence to J. M. Stewart.

Additional information

The online version of the original article can be found at doi: http://dx.doi.org/10.1007/s10637-017-0438-z

Rights and permissions

This article is published under an open access license. Please check the 'Copyright Information' section for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fu, S., Hirte, H., Welch, S. et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs 35, 397 (2017). https://doi.org/10.1007/s10637-017-0455-y

Download citation